Full-Time

Pharmacy Services Manager

Posted on 11/23/2025

OneOncology

OneOncology

501-1,000 employees

Operates network of community oncology practices

No salary listed

Remote in USA

Remote

Category
Medical, Clinical & Veterinary (2)
,
Requirements
  • Registered nurse with associate or bachelor’s degree in nursing
  • Minimum 2-year oncology experience
  • Experience with Flatiron Health OncoEMR software
  • Current unrestricted nursing hours
  • Flexible hours to support projects assigned
  • Knowledge of cancer and urology medications, dosing, and proper admixture with ability to access resources as required
  • Knowledge of clinic procedures and operations
  • Strong people skills for pharmacy staff and practice interactions
  • Ability to use computers and software applications (MS Office products)
  • Excellent written and oral communication
  • Excellent attention to detail and organizational skills
  • Excellent project management skills with an emphasis on detail and follow-through
  • Excellent written and verbal communication and presentation skills
Responsibilities
  • Assists the Vice President of Pharmacy Services and Director of Pharmacy Services at corporate and practice level incoming clinical information requests
  • Acts as a liaison and resource to provide support for regimen build support at UUG practices
  • Will demonstrate regimen build and clinical trial protocol evaluation expertise through accurate and complete research regimen builds with incorporation of necessary UUG Research and Individual Practice components
  • Assists the Director of Pharmacy with the Shared Pharmacy Services program, including but not limited to education for practices on the shared services model and performing drug switches within individual practice’s instance of OncoEMR and Veradigm
  • Participates in developing communication for all clinical upgrades and/or changes within OncoEMR and Veradigm for UUG practices
  • Participates in the management of clinical projects directly related to drug regimen maintenance, as well as assisting in prioritizing and determining timelines for implementation of projects
  • Triage and address, along with Director of Pharmacy, any practice clinical concerns/complaints surrounding NCCN and FH regimens

OneOncology builds a network of US oncology practices by partnering with community clinics to broaden access to advanced cancer care. It supports partner sites by investing in clinical, operational, and technical capabilities and by providing a shared data analytics and technology platform to improve care and efficiency. Local practice leadership stays in place, preserving continuity and local expertise while gaining access to centralized resources. The goal is to improve patient outcomes in community settings and sustain high-quality, locally led oncology services by coordinating care through a data-driven platform.

Company Size

501-1,000

Company Stage

Acquired

Total Funding

$5.9B

Headquarters

Nashville, Tennessee

Founded

2018

Simplify Jobs

Simplify's Take

What believers are saying

  • Cencora's $7.4B acquisition completed, strengthening specialty pharmaceutical MSO.
  • Acquired GenesisCare in Florida, relaunching as SunState with 100+ physicians.
  • Expanded to 20 anchor practices across 16 states with radiation, theranostics.

What critics are saying

  • Cencora acquisition eliminates independence, shifts focus to drug distribution.
  • US Oncology Network poaches practices like Astera using McKesson scale.
  • CMS Oncology Care Model 2.0 slashes reimbursements for high-cost regimens.

What makes OneOncology unique

  • Physician-led platform empowers independent oncology practices with data analytics.
  • OneR network presented 23 ASCO 2025 abstracts, including two Best of ASCO.
  • Partners with START to launch early phase trials at LACN, CCBD, Astera.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Business Wire
Dec 16th, 2025
Cencora Accelerates OneOncology Acquisition, Extending Solutions Offering for Community Oncology

Cencora, Inc. (NYSE: COR) today announced it has entered into a definitive agreement to acquire the majority of the outstanding equity interests that it does...

Stock Titan
Dec 15th, 2025
Cencora to acquire OneOncology for $3.6B, raising long-term EPS guidance to 10-14%

Cencora has entered into a definitive agreement to acquire the majority stake it doesn't own in OneOncology, a physician-led oncology management services organisation, from TPG. The transaction values OneOncology's enterprise at $7.4 billion, with Cencora paying approximately $5 billion in total cash consideration, including debt retirement. OneOncology has grown substantially since Cencora's initial investment, attracting leading practices through its physician-led approach. The acquisition will strengthen Cencora's specialty solutions and enhance patient access to pharmaceuticals across communities. The deal is expected to close by the end of Cencora's fiscal 2026 second quarter, subject to regulatory approvals. Cencora plans to fund the transaction through new debt financing and expects the acquisition to be approximately neutral to adjusted diluted EPS in the first twelve months. The company has raised its long-term guidance to reflect OneOncology's expected contribution.

PR Newswire
Oct 8th, 2025
OneOncology Acquires GenesisCare in Florida

OneOncology has expanded in Florida by acquiring GenesisCare and will relaunch as SunState Medical Specialists. The acquisition includes over 100 physicians specializing in urology, oncology, and surgical fields, providing care across Florida. Significant investments are planned to upgrade technology and expand access to advanced clinical services.

WVNEWS
Sep 23rd, 2025
OneOncology Appoints Todd Doyle, MD as Chief of Radiation Oncology

OneOncology appoints Todd Doyle, MD as Chief of Radiation Oncology.

INACTIVE